[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc (HLN) Form 6-K: The company reports the purchase and cancellation of 1,281,000 ordinary shares (£0.01 par) on 1 Aug 2025, executed on the London Stock Exchange as part of the second tranche of its share-buyback programme announced 31 Jul 2025.

• Pricing: highest 368.4000p, lowest 359.0000p, volume-weighted average 364.8941p.
• The repurchase equals roughly 0.014% of the 8.98 bn shares outstanding.
• Post-settlement share capital totals 8,986,370,560, of which 3,880,205 are treasury shares, leaving 8,982,490,355 shares with voting rights.

The updated voting share count should be used for FCA disclosure thresholds. A trade-by-trade breakdown is available via the linked RNS PDF and on Haleon’s investor website. No additional financial or operational disclosures accompany this filing.

Insights

Financial Analyst

TL;DR: Small buyback continuation; negligible EPS effect; signals steady capital return, overall neutral impact.

Buying 1.28 m shares (~0.014% of float) for cancellation marginally lowers share count but is too small to materially change EPS or valuation. The action confirms the previously announced buyback schedule and suggests management confidence in intrinsic value, yet the scale is immaterial versus a £30 bn+ market cap. Investors should note the updated voting share figure (8.982 bn) for reporting thresholds. No guidance or performance data were provided, so this filing is unlikely to move the stock.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐                    

EXHIBIT INDEX

Exhibit Number	Description
99.1	04 August 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

04 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,281,000 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	01 August 2025	01 August 2025	01 August 2025
Number of Shares purchased:	1,281,000	-	-
Highest price paid per Share (p):	368.4000	-	-
Lowest price paid per Share (p):	359.0000	-	-
Volume weighted average price paid per Share (p):	364.8941	-	-

Following the settlement of the above, the Company's registered share capital is 8,986,370,560 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,982,490,355 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/7222T_1-2025-8-1.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: August 04, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many Haleon (HLN) shares were repurchased?

The company bought 1,281,000 ordinary shares on 1 Aug 2025.

What prices did HLN pay for the shares?

Highest price 368.4000p, lowest 359.0000p, VWAP 364.8941p.

What is Haleon's updated voting share count?

After cancellation, voting shares total 8,982,490,355.

How significant is the buyback relative to total shares?

The 1.28 m shares equal around 0.014% of the 8.98 bn shares outstanding.

Where can I find the detailed trade breakdown?

See the PDF at http://www.rns-pdf.londonstockexchange.com/rns/7222T_1-2025-8-1.pdf or Haleon’s investor site.

Does this filing include earnings or guidance updates?

No, the Form 6-K solely reports the share repurchase transaction.